Evidence map›Paper›PMID 36145835›Full record

ReviewPlants (Basel, Switzerland)2022

Genetic Containment for Molecular Farming.

Amy L Klocko

Open access · goldAbstract readReview
In one paragraph

Review in Plants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Amy L KlockoDepartment of Biology, University of Colorado Colorado Springs, Colorado Springs, CO 80918, USA.ORCID 0000-0001-6495-8400
University of Colorado Colorado Springs · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plant molecular farming can provide humans with a wide variety of plant-based products including vaccines, therapeutics, polymers, industrial enzymes, and more. Some of these products, such as Taxol, are produced by endogenous plant genes, while many others require addition of genes by artificial gene transfer. Thus, some molecular farming plants are transgenic (or cisgenic), while others are not. Both the transgenic nature of many molecular farming plants and the fact that the products generated are of high-value and specific in purpose mean it is essential to prevent accidental cross-over of molecular farming plants and products into food or feed. Such mingling could occur either by gene flow during plant growth and harvest or by human errors in material handling. One simple approach to mitigate possible transfer would be to use only non-food non-feed species for molecular farming purposes. However, given the extent of molecular farming products in development, testing, or approval that do utilize food or feed crops, a ban on use of these species would be challenging to implement. Therefore, other approaches will need to be considered for mitigation of cross-flow between molecular farming and non-molecular-farming plants. This review summarized some of the production systems available for molecular farming purposes and options to implement or improve plant containment.

Indexed as

biopharmaceuticalsgene flowgenetic modificationmolecular farmingplant expression systemstransgenic plants

Identifiers

PMID36145835
PMCPMC9501302
OpenAlexW4296360634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.